Natco Pharma receives final approval from USFDA for Azacitidine for Injection

27 Jun 2017 Evaluate

Natco Pharma has received final approval of Abbreviated New Drug Application (ANDA) from the US Food and Drug Administration (USFDA) for Azacitidine for Injection, 100mg per Vial, Single-Dose Vial, a generic version of Vidaza by Celgene Corporation.

NATCO and its marketing partner Breckenridge Pharmaceutical, Inc. (BPI) plan to launch this product in the USA market in the near future.

Vidaza is a prescription anti-cancer chemotherapy drug that is indicated to treat myelodysplastic syndrome (MDS). Vidaza generated total combined sales of $188 million for the twelve-month period ending April, 2017, based on industry sales data.



Natco Pharma Share Price

890.00 -13.55 (-1.50%)
01-Jan-2026 10:09 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1714.40
Dr. Reddys Lab 1254.60
Cipla 1504.25
Zydus Lifesciences 910.05
Lupin 2084.90
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×